C12N1/28

Dihomo-γ-linolenic acid-containing microbial oil and dihomo-γ-linolenic acid-containing microbial biomass

A microbial oil comprising dihomo--linolenic acid as a constituent fatty acid of an oil, the microbial oil has a content, in terms of a weight ratio of arachidonic acid relative to dihomo--linolenic acid (arachidonic acid/dihomo--linolenic acid) of less than 1/13. Preferably, the microbial oil has a triglyceride content of greater than or equal to 70% by weight, and a saturated fatty acid content of less than or equal to 40% by weight. Moreover, a lower alcohol ester of dihomo--linolenic acid or a free fatty acid of dihomo--linolenic acid obtained from the microbial oil is provided.

Dihomo-γ-linolenic acid-containing microbial oil and dihomo-γ-linolenic acid-containing microbial biomass

A microbial oil comprising dihomo--linolenic acid as a constituent fatty acid of an oil, the microbial oil has a content, in terms of a weight ratio of arachidonic acid relative to dihomo--linolenic acid (arachidonic acid/dihomo--linolenic acid) of less than 1/13. Preferably, the microbial oil has a triglyceride content of greater than or equal to 70% by weight, and a saturated fatty acid content of less than or equal to 40% by weight. Moreover, a lower alcohol ester of dihomo--linolenic acid or a free fatty acid of dihomo--linolenic acid obtained from the microbial oil is provided.

Biological methods for preparing a fatty dicarboxylic acid

The technology relates in part to biological methods for producing a fatty dicarboxylic acid and engineered microorganisms capable of such production.

Biological methods for preparing a fatty dicarboxylic acid
09738913 · 2017-08-22 · ·

The technology relates in part to biological methods for producing a fatty dicarboxylic acid and engineered microorganisms capable of such production.

Biological methods for preparing a fatty dicarboxylic acid
09738913 · 2017-08-22 · ·

The technology relates in part to biological methods for producing a fatty dicarboxylic acid and engineered microorganisms capable of such production.

Method for producing retinoid from microorganism

The present invention relates to a method for producing retinoid from a microorganism, and more specifically, to a method for effectively obtaining retinoid, which lacks stability, from a microorganism by cultivating the microorganism capable of producing retinoid in a medium containing a lipophilic substance, and separating retinoid from the lipophilic substance.

Method for producing retinoid from microorganism

The present invention relates to a method for producing retinoid from a microorganism, and more specifically, to a method for effectively obtaining retinoid, which lacks stability, from a microorganism by cultivating the microorganism capable of producing retinoid in a medium containing a lipophilic substance, and separating retinoid from the lipophilic substance.

BIOLOGICAL METHODS FOR PREPARING A FATTY DICARBOXYLIC ACID

The technology relates in part to biological methods for producing a fatty dicarboxylic acid and engineered microorganisms capable of such production.

Combined F2-isoprostane and myleoperoxidase detection, a risk indicator for cardiovascular disease

Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from the general population or a select population of human subjects. Such comparison characterizes the test subject's risk of developing CVD.

Combined F2-isoprostane and myleoperoxidase detection, a risk indicator for cardiovascular disease

Diagnostic tests for characterizing an individual's risk of developing or having a cardiovascular disease. In one embodiment the present diagnostic test comprises determining the level of myeloperoxidase (MPO) activity in a bodily sample obtained from the individual or test subject. In another embodiment, the diagnostic test comprises determining the level of MPO mass in a bodily sample obtained from the test subject. In another embodiment, the diagnostic test comprises determining the level of one or more select MPO-generated oxidation products in a bodily sample obtained from the test subject. The select MPO-generated oxidation products are dityrosine, nitrotyrosine, methionine sulphoxide or an MPO-generated lipid peroxidation products. Levels of MPO activity, MPO mass, or the select MPO-generated oxidation product in bodily samples from the test subject are then compared to a predetermined value that is derived from measurements of MPO activity, MPO mass, or the select MPO-generated oxidation product in comparable bodily samples obtained from the general population or a select population of human subjects. Such comparison characterizes the test subject's risk of developing CVD.